Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study
Highlights • Survival outcomes of patients with NSCLC without targetable mutations remain depressing. • Sintilimab plus docetaxel as second-line therapy improves progression-free survival outcomes. • Sintilimab plus docetaxel is safe and well-tolerated. • Patients detected with high PD-L1 expression...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-09-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-022-10045-0 |
| _version_ | 1828113163455823872 |
|---|---|
| author | Yongchang Zhang Lianxi Song Liang Zeng Yi Xiong Li Liu Chunhua Zhou Haiyan Yang Zhan Wang Qing Xia Wenjuan Jiang Qinqin Xu Nong Yang |
| author_facet | Yongchang Zhang Lianxi Song Liang Zeng Yi Xiong Li Liu Chunhua Zhou Haiyan Yang Zhan Wang Qing Xia Wenjuan Jiang Qinqin Xu Nong Yang |
| author_sort | Yongchang Zhang |
| collection | DOAJ |
| description | Highlights • Survival outcomes of patients with NSCLC without targetable mutations remain depressing. • Sintilimab plus docetaxel as second-line therapy improves progression-free survival outcomes. • Sintilimab plus docetaxel is safe and well-tolerated. • Patients detected with high PD-L1 expression in circulating tumor cells (≥32.5%, median level in 30 patients) achieved significantly higher ORR, PFS and OS. • Patients detected with PD-L1 < 1% and CD8 ≥ 1% expression from their baseline tissue samples had significantly higher ORR (p = 0.026). |
| first_indexed | 2024-04-11T12:02:15Z |
| format | Article |
| id | doaj.art-d76394190b1d4ef0bd44e66f043efd2c |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-04-11T12:02:15Z |
| publishDate | 2022-09-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-d76394190b1d4ef0bd44e66f043efd2c2022-12-22T04:24:50ZengBMCBMC Cancer1471-24072022-09-0122111310.1186/s12885-022-10045-0Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker studyYongchang Zhang0Lianxi Song1Liang Zeng2Yi Xiong3Li Liu4Chunhua Zhou5Haiyan Yang6Zhan Wang7Qing Xia8Wenjuan Jiang9Qinqin Xu10Nong Yang11Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South UniversityDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South UniversityDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South UniversityDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South UniversityDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South UniversityDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South UniversityDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South UniversityDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South UniversityState Key Laboratory for Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Department of Oncology, Shanghai Jiao Tong University School of MedicineDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South UniversityDepartment of Medical Oncology, Qinghai Provincial People’s HospitalDepartment of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South UniversityHighlights • Survival outcomes of patients with NSCLC without targetable mutations remain depressing. • Sintilimab plus docetaxel as second-line therapy improves progression-free survival outcomes. • Sintilimab plus docetaxel is safe and well-tolerated. • Patients detected with high PD-L1 expression in circulating tumor cells (≥32.5%, median level in 30 patients) achieved significantly higher ORR, PFS and OS. • Patients detected with PD-L1 < 1% and CD8 ≥ 1% expression from their baseline tissue samples had significantly higher ORR (p = 0.026).https://doi.org/10.1186/s12885-022-10045-0Sintilimab plus docetaxelNSCLCCTC-PD-L1Multiplex immunofluorescence |
| spellingShingle | Yongchang Zhang Lianxi Song Liang Zeng Yi Xiong Li Liu Chunhua Zhou Haiyan Yang Zhan Wang Qing Xia Wenjuan Jiang Qinqin Xu Nong Yang Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study BMC Cancer Sintilimab plus docetaxel NSCLC CTC-PD-L1 Multiplex immunofluorescence |
| title | Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study |
| title_full | Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study |
| title_fullStr | Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study |
| title_full_unstemmed | Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study |
| title_short | Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study |
| title_sort | sintilimab plus docetaxel as second line therapy of advanced non small cell lung cancer without targetable mutations a phase ii efficacy and biomarker study |
| topic | Sintilimab plus docetaxel NSCLC CTC-PD-L1 Multiplex immunofluorescence |
| url | https://doi.org/10.1186/s12885-022-10045-0 |
| work_keys_str_mv | AT yongchangzhang sintilimabplusdocetaxelassecondlinetherapyofadvancednonsmallcelllungcancerwithouttargetablemutationsaphaseiiefficacyandbiomarkerstudy AT lianxisong sintilimabplusdocetaxelassecondlinetherapyofadvancednonsmallcelllungcancerwithouttargetablemutationsaphaseiiefficacyandbiomarkerstudy AT liangzeng sintilimabplusdocetaxelassecondlinetherapyofadvancednonsmallcelllungcancerwithouttargetablemutationsaphaseiiefficacyandbiomarkerstudy AT yixiong sintilimabplusdocetaxelassecondlinetherapyofadvancednonsmallcelllungcancerwithouttargetablemutationsaphaseiiefficacyandbiomarkerstudy AT liliu sintilimabplusdocetaxelassecondlinetherapyofadvancednonsmallcelllungcancerwithouttargetablemutationsaphaseiiefficacyandbiomarkerstudy AT chunhuazhou sintilimabplusdocetaxelassecondlinetherapyofadvancednonsmallcelllungcancerwithouttargetablemutationsaphaseiiefficacyandbiomarkerstudy AT haiyanyang sintilimabplusdocetaxelassecondlinetherapyofadvancednonsmallcelllungcancerwithouttargetablemutationsaphaseiiefficacyandbiomarkerstudy AT zhanwang sintilimabplusdocetaxelassecondlinetherapyofadvancednonsmallcelllungcancerwithouttargetablemutationsaphaseiiefficacyandbiomarkerstudy AT qingxia sintilimabplusdocetaxelassecondlinetherapyofadvancednonsmallcelllungcancerwithouttargetablemutationsaphaseiiefficacyandbiomarkerstudy AT wenjuanjiang sintilimabplusdocetaxelassecondlinetherapyofadvancednonsmallcelllungcancerwithouttargetablemutationsaphaseiiefficacyandbiomarkerstudy AT qinqinxu sintilimabplusdocetaxelassecondlinetherapyofadvancednonsmallcelllungcancerwithouttargetablemutationsaphaseiiefficacyandbiomarkerstudy AT nongyang sintilimabplusdocetaxelassecondlinetherapyofadvancednonsmallcelllungcancerwithouttargetablemutationsaphaseiiefficacyandbiomarkerstudy |